Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion type Assertion NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_head.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion description "[In the Stage I/II GCs, the clinicopathologic, phenotypic and proliferative characteristics of GCs from exposed and nonexposed patients did not differ significantly; however, versican and osteonectin were expressed at much lower levels in the area of tumor-associated stroma of exposed patients than in nonexposed patients (p = 0.026 and p = 0.024, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_provenance.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion evidence source_evidence_literature NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_provenance.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion SIO_000772 19058179 NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_provenance.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion wasDerivedFrom befree-20140225 NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_provenance.
- NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_assertion wasGeneratedBy ECO_0000203 NP679800.RAopGtEh62ZMo0T7OE27823iAz-gyEepMXU_9KRtSA0BE130_provenance.